Digital Science
LONDON and Halle, Germany, March 20 /PRNewswire/
In a sea of information, AI-based solutions will help focus industry research and development.
Digital Science is positioning itself to play an even bigger role in the drug research that is so important to the pharmaceutical industry, by helping the industry to sift through the information overload and focus on the research aspects that really matter.
To achieve this, Digital Science – a technology company serving stakeholders across the research ecosystem – has fully acquired OntoChem GmbH, a company specializing in AI-based solutions for finding and extracting key information from internal and external data and text, in particular from published research.
After a partnership of almost two years between the two companies, OntoChem has become the newest member of the Digital Science family. OntoChem will continue to operate as part of the product portfolio of Digital Science Dimensions – the world‘s largest provider of connected research databases and data infrastructure – which will be of strategic value to both the pharmaceutical industry and the broader healthcare and medical sectors.
OntoChem, based in Halle (Saxony-Anhalt), has 18 years of experience in the development of innovative technologies for industry. OntoChem’s text mining, natural language processing and semantic data extraction technologies enable companies to extract information from both unstructured and structured data and transform it into new knowledge for research and discovery as well as for strategic decisions. These tools are used by pharmaceutical, materials science and technology-oriented companies.
OntoChem currently indexes more than 600 million public documents with 30 million semantic ontology concepts and 150 million synonyms in domains such as drugs, proteins, diseases, drugs, materials, methods, devices, species and many more. For the active ingredients alone, OntoChem accesses data from the research of 2 billion active ingredients that are of crucial importance for drug research.
Lutz WeberCEO of OntoChem, said: “More and more pharmaceutical companies are augmenting their research using AI, machine learning and other technologies to accelerate their discoveries and translate them into real-world results
One of the biggest problems for pharmaceutical companies is the ‘data dilemma’ – there is so much information to sift through that it can be difficult to know where to look or what to focus on. Even in a field like cancer or diabetes, a wealth of new knowledge is being gained every day in very specific research areas. Here we can make a contribution with our work by supporting companies in their discoveries and decisions.
We at OntoChem are excited to become part of Digital Science – this means significant support of our long-term vision to extract global and comprehensive semantic knowledge from scientific and related documents or databases, both from corporate and public sources.”
Christian Herzog, Chief Product Officer of Digital Science and co-founder of Dimensions, said: “OntoChem is a strong strategic fit for Digital Science in combination with our core product Dimensions. The pharmaceutical industry will benefit directly from this acquisition, and through their discoveries, our work will benefit the health of individuals and communities around the world.
OntoChem’s highly specialized search and extraction tools combined with Dimensions’ access to data from hundreds of millions of research papers, linked grants, patents and clinical trials and access to data via Google BigQuery create a powerful analytical environment. We already work with life science companies, including those in drug discovery and development, and we expect to continue and expand this in the future.
In addition to industry, research institutions, governments and funding organizations will benefit from these unique insights, suitable for discovery and decision-making.”
Information on digital science
Digital Science is a technology company that strives to make research more efficient. We invest in, encourage and support innovative companies and technologies that make all parts of the research process more open and effective. Our portfolio includes renowned brands such as Altmetric, Dimensions, Figshare, ReadCube, Symplectic, IFI Claims Patent Services, Overleaf, Ripeta, Writefull and metaphacts. We believe that together we can help researchers make a difference. Visit www.digital-science.com and follow @digitalsci on Twitter or LinkedIn.
Information about dimensions
Dimensions, part of Digital Science, is the largest provider of connected research databases and data infrastructure, transforming research discovery by providing access to grants, publications, clinical studies, patents and policy documents in one place. www.dimensions.ai
Information about OntoChem GmbH
OntoChem offers powerful and highly customizable text analysis and data mining products that can be tailored to each client’s specific needs. OntoChem’s main products are: SciWalker – a semantic search and analytics solution to support life science communities; OntoChem processor – a semantic processor tool that allows customers to enter text from any source; OntoChem Ontologies – a set of ontologies for specific medical and biochemical applications.
OntoChem’s information discovery tools are used by small and large life and materials science companies to find information through automated indexing and analysis of internal and external data collections. This data provides the raw material for AI and machine learning methods for predictive drug development or material design. OntoChem is proud to work with some of the most influential companies in the pharmaceutical, chemical, specialty chemical, materials science, publishing and IT sectors. Visit www.ontochem.com.
View original content: https://www.prnewswire.com/news-releases/digital-science-verstarkt-die-unterstutzung-der-pharmaindustrie-nach-der-ubernahme-von-ontochem-301845134.html
Press contact:
Simon Linacre,
Head of Content,
Brand & Press,
Digital Science: Mobil: +44 7484 381477,
[email protected] / David Ellis,
Press,
PR & Social Manager,
Digital Science: Mobil: +61 447 783 023,
[email protected]
Original content from: Digital Science, transmitted by news aktuell